Nomogram for Predicting the Overall Survival of Patients With Breast Cancer With Pathologic Nodal Status N3 |
| |
| Institution: | 1. Radiotherapy Unit, University of Florence, Florence, Italy;2. Diagnostic Senology Unit, University of Florence, Florence, Italy;3. Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Center (ISPO), University of Florence, Florence, Italy;4. Breast Radiology Service, Policlinico Hospital, Bari, Italy;5. Department of Surgery, University of Florence, Florence, Italy;6. Department of Pathology, University of Florence, Florence, Italy;1. Department of Radiation Oncology, Ewha Womans University College of Medicine, Seoul, Republic of Korea;2. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;3. Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea;4. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;5. Department of Radiation Oncology, Chonbuk National University Hospital, Jeonju, Republic of Korea;6. Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Republic of Korea;7. Department of Radiation Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea;8. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea;9. Department of Radiation Oncology, Wonju Severance Christian Hospital, Wonju, Republic of Korea;10. Department of Radiation Oncology, Hanyang University College of Medicine, Seoul, Republic of Korea;11. Department of Radiation Oncology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Uijeongbu, Republic of Korea;1. Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA;2. Department of Radiation Oncology, Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, USA;3. Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX, USA;4. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA;1. Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China;2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;3. Department of Finance and Control Sciences, School of Mathematical Sciences, Fudan University, Shanghai, China;4. Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, China;5. Key Laboratory of Systems Biology, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China;6. School of Life Science and Technology, ShanghaiTech University, Shanghai, China;7. Institutes of Biomedical Sciences, Fudan University, Shanghai, China;1. Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center, Medical University of Graz, Austria;2. Division of Internal Medicine, Outpatient Department Graz, Austria;3. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Comprehensive Cancer Center, Medical University of Graz, Austria;4. Division of Clinical Oncology, Department of Medicine, Comprehensive Cancer Center, Medical University of Graz, Austria |
| |
| Abstract: | BackgroundPatients with breast cancer with pathologic N3 (pN3) lymph node status have been proven to have a poor prognosis. This study aimed to establish a nomogram to predict overall survival (OS) in patients with pN3 breast cancer.Materials and MethodsThe eligible patients from the Surveillance, Epidemiology, and End Results (SEER) database were randomly divided into training and validation cohorts. χ2 tests and survival curves were performed to define the consistency between these 2 cohorts. Univariate and multivariate logistic regressions were carried out to identify the independent clinicopathologic factors of patients with pN3 breast cancer. A nomogram was developed and validated internally and externally by a calibration curve and compared with the seventh edition American Joint Committee on Cancer TNM staging classification in discrimination ability.ResultsRace, age at diagnosis, marital status, grade, T stage, N stage, breast cancer subtype, surgery, radiotherapy, and chemotherapy were independent predictive factors of OS in pN3 breast cancer. We developed a nomogram to predict 1-, 3-, and 5-year OS and further validated it in both cohorts, demonstrating better prediction capacity in OS than that of the seventh edition American Joint Committee on Cancer TNM staging classification (area under the curve in the receiver operating characteristic curve, 0.745 and 0.611 in the training cohort and 0.768 and 0.624 in the validation cohort, respectively).ConclusionWe have developed and validated the first nomogram for predicting the survival of pN3 breast cancer. This nomogram accurately and reliably predicted the OS of patients with pN3 breast cancer. However, more prognostic factors need to be further explored to improve the nomogram. |
| |
| Keywords: | AJCC TNM staging Lymph node metastasis Predictive tool SEER Survival analysis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
